Ipca Laboratories

    IPCALAB
    Pharma
    ₹1,854.10
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹47,039 Cr

    P/E
    33.54
    Day range
    ₹1,834.00 – ₹1,882.80
    52-week range
    ₹1,361.70 – ₹2,038.00
    Volume
    2.43 L
    Open
    ₹1,834.40
    Prev close
    ₹1,834.40

    Latest results · Q2 FY27(consolidated)Revenue ₹2,910 Cr+13.8%Profit ₹389 Cr+38.8%Margin 13.4%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 69 / 100

    Factor percentiles

    Value44
    Quality70
    Momentum72
    Low volatility92

    Derived metrics

    Earn. yield
    3.0%
    Graham no.
    ₹659.53
    vs Graham
    -64.4%
    ROE ÷ P/B
    2.9%
    12-1 mom.
    +36.3%
    Return / vol
    1.27
    Magic Formula
    #322
    Piotroski
    6/6
    FCF yield
    1.0%
    PEG
    0.86

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Ipca LaboratoriesIPCALAB₹47,039 Cr33.545.4615.8%17.0%23.0%0.09+13.8%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1d ago

    Headlines about Ipca Laboratories from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    32.8
    Price / Book
    5.42
    ROE (FY26)
    15.8%
    ROCE (latest year)
    17%
    Dividend yield
    0.32%

    Moving averages (NSE)

    20-day
    ₹1,923.94
    Price below
    50-day
    ₹1,935.5
    Price below
    200-day
    ₹1,700.51
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +15.7%
    Profit 3Y CAGR
    +35.2%
    Revenue YoY (Sep 2026)
    +13.8%
    Profit YoY (Sep 2026)
    +38.4%
    Operating margin
    23.0%
    Net margin
    13.4%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr1K Cr2K Cr3K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the split of 10 Jan 2022: earlier bars are per pre-split share.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹2₹4₹6₹8

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales2,0532,0332,0932,3552,2452,2472,3092,5562,3922,3882,7882,910
    Expenses1,7221,7111,7001,9131,7821,8181,8922,0121,8591,9052,1192,236
    Operating Profit331322393441463429416545533484670673
    OPM %16%16%19%19%21%19%18%21%22%20%24%23%
    Other Income91-118212620-17933-303848251
    Interest332924231722192018201213
    Depreciation100989910098100100103108107111115
    Profit before tax28977290345368128331392446404572547
    Tax %23%96%31%29%25%49%29%28%18%24%26%28%
    Net Profit221119924627664233281364307424389
    EPS in Rs₹7.09₹2.35₹7.58₹9.05₹9.78₹2.67₹9.19₹11.14₹12.86₹11.79₹15.84₹14.79

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days77

    +22 days since Mar 2021

    Inventory Days353

    +16 days since Mar 2021

    Days Payable122

    -18 days since Mar 2021

    Cash Conversion Cycle308

    +57 days since Mar 2021

    Working Capital Days109

    +6 days since Mar 2021

    Strengths, risks & growth

    Ipca Laboratories is an integrated pharmaceutical company manufacturing branded and generic formulations, APIs and intermediates. Indian branded formulations are its core profit engine, complemented by formulation exports across Europe, Africa, the Americas, Asia, CIS and Australasia. The consolidated business includes Unichem Laboratories and its US, Brazil, Europe and South Africa operations. [1]

    Strengths

    • Company has reduced debt.
    • Company is almost debt free.

    Risks

    • Stock is trading at 5.45 times its book value
    • Company has a low return on equity of 12.9% over last 3 years.

    Compounded Sales Growth

    10 Years
    +13%
    5 Years
    +12%
    3 Years
    +16%
    TTM
    +12%

    Compounded Profit Growth

    10 Years
    +30%
    5 Years
    +1%
    3 Years
    +37%
    TTM
    +46%

    Stock Price CAGR

    10 Years
    +21%
    5 Years
    +12%
    3 Years
    +20%
    1 Year
    +27%

    Return on Equity

    10 Years
    +14%
    5 Years
    +13%
    3 Years
    +13%
    Last Year
    +16%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter44.72%44.72%44.72%44.72%0.00 pp
    FII10.62%10.63%10.72%11.53%+0.81 pp
    DII36.99%37.13%37.04%36.60%-0.44 pp
    Government0.32%0.32%0.32%0.00%-0.32 pp
    Public7.33%7.21%7.19%7.15%-0.04 pp

    Filed with NSE for Sept 2026: promoters 44.72%, public 55.28%

    Analysts & fund holdings

    82%
    82% recommend buy
    17 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E33.5 vs 45.2
    Sector P/B6.05
    Beta0.19

    Who holds the shares, quarter by quarter

    Mutual funds 31.07% (-0.08 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters44.7%
    • Foreign institutions11.5%
    • Mutual funds31.1%
    • Insurance4.8%
    • Other domestic institutions0.5%
    • Retail5.7%
    • Others1.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Mid Cap Fund7.39%3.47%+0.47 pp
    Kotak Mid Cap Fund5.03%3.68%+0.57 pp
    Axis Midcap Fund1.63%2.32%+0.28 pp
    Nippon India Growth Mid Cap Fund1.30%1.22%+0.15 pp
    DSP Midcap Fund1.17%2.94%+0.49 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    29.8%
    Downside volatility
    24.5%
    Worst 5% of days
    2.6%
    Average of that tail
    3.5%
    Max drawdown (1Y)
    12.0%
    Below its peak
    7.7%

    Against the market

    Beta vs Nifty 50
    -0.02
    Correlation
    -0.01
    Relative strength (3M)
    -5.5%
    ATR (14)
    3.4%

    Return

    Return 1M
    +1.2%
    Return 3M
    -1.6%
    Return 6M
    +12.6%
    Return 1Y
    +37.9%
    vs 200-day average
    +9.0%

    Momentum

    RSI (14)
    39.8
    MACD histogram
    -11.36
    Stochastic %K
    16.9
    ADX (14)
    22.7
    +DI / −DI
    7.6 / 20.4
    Money flow index
    40.1

    Participation

    Delivery (20d avg)
    54.7%
    vs its 60-day baseline
    -1.2 pts
    Volume vs 20-day
    -0.4σ
    Close vs day's VWAP
    -0.5%
    52-week position
    79 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    6 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹486 Cr
    FCF yield
    1.0%
    Cash conversion
    0.96
    Accruals ratio
    0.003
    Net debt
    ₹546 Cr
    Net debt / equity
    0.06
    EV / sales
    4.54
    PEG
    0.86
    Capex intensity
    6.8%
    Revenue CAGR
    18.8%
    Profit CAGR
    232.9%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹44.5 L
    0 buys · ₹0
    1 sells · ₹44.5 L
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    MANISH KUMAR JAIN
    Market Sale
    Sell3,000₹44.5 L18 Feb 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹6.00

      Dividend - Rs 6 Per Share

      7 Aug 2026
      ex-date
    • dividend
      ₹2.00

      Dividend - Rs 2 Per Share

      5 Aug 2025
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      27 Nov 2024
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      6 Aug 2024
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      22 Nov 2023
      ex-date
    • dividend
      ₹4.00

      Interim Dividend - Rs 4 Per Share

      22 Nov 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      3 Aug 2022
      ex-date
    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 2/- Per Share To Re 1/- Per Share

      10 Jan 2022
      ex-date
    • dividend
      ₹8.00

      Interim Dividend - Rs 8 Per Share

      22 Nov 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      26 Aug 2021
      ex-date
    • dividend
      ₹8.00

      Interim Dividend - Rs 8 Per Share

      13 Nov 2020
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      10 Sept 2020
      ex-date
    • dividend
      ₹5.00

      Interim Dividend - Rs 5 Per Share

      18 Feb 2020
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      6 Aug 2019
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend- Re 1 Per Share

      2 Aug 2018
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 1/- Per Share

      27 Jul 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      4 Aug 2016
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting / Dividend - Re 1/- Per Share

      22 Jul 2015
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting / Final Dividend - Rs 2.50/- Per Share

      18 Jul 2014
      ex-date
    • dividend
      ₹2.50

      Interim Dividend Rs.2.50 Per Share (Purpose Revised)

      31 Oct 2013
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Transcript of Conference Call held on 05.11.2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copy of Newspaper Publication

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio Link of Conference Call held on 05.11.2026

    Result
    Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended 30.09.2026

    Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026

    Board Meeting
    Board Meeting Outcome for Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended 30.09.2026

    Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Schedule of Conference Call

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The Second Quarter And Half Year Ended 30.09.2026

    Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Standalone and Consolidated ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    The Company has enclosed herewith certificate recived from RTA under reg 74 5 for the quarter ended 30.09.2026.

    Insider Trading / SAST
    Closure of Trading Window
    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Transcript of Conference Call

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audiolink for Conference Call held on 14.08.2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copy of Newspaper Publication

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    76th AGM - Voting Results and Scrutinizer Report

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of AGM

    Result
    Standalone And Consolidated Unaudited Financial Results For Q1FY27

    Standalone and Consolidated Unaudited Financial Results for Q1FY27

    Filed with BSE (scrip 524494); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Buyback - buyback

      IPCA Laboratories Limited - buyback

      19 Nov 2009
      Read on SEBI
    • Buyback - Corrigendum to Public Announcement

      Ipca Laboratories Ltd. - Corrigendum to Public Announcement

      11 Dec 2008
      Read on SEBI
    • Buyback - Public Notice

      IPCA Laboratories Ltd. - Public Notice

      14 Nov 2008
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Ipca Laboratories: common questions

    Answered from the figures on this page.

    Ipca Laboratories last traded at ₹1,854.10 (NSE, as of 18 Nov 2026). The last session moved it up 1.07%.

    Ipca Laboratories is valued at about ₹47,039 crore (NSE, as of 18 Nov 2026).

    Ipca Laboratories trades at a price-to-earnings ratio of 33.54 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Ipca Laboratories has traded between ₹1,361.70 and ₹2,038.00 over the past 52 weeks, to 18 Nov 2026. It is currently 73% of the way up that range.

    Ipca Laboratories (IPCALAB) is classified under Pharma on this site's screener.